BAAR, Switzerland / Oct 01, 2025 / Business Wire / Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three- and nine-month periods that ended September 30, 2025. To access the conference call by... Read More

METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following stereotactic radiation of the metastases Results from the METIS trial published in the International Journal of Radiation Oncology Biology and Physics BAAR, Switzerland / Sep 29, 2025 / Business Wire / Novocure (NASDAQ: NVCR)... Read More

Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy Ministry of Health, Labour and Welfare approval is supported by the results of the pivotal Phase 3 LUNAR trial that showed a statistically significant and clinically meaningful improvement in median overall survival in NSCLC patients... Read More

BAAR, Switzerland / Aug 28, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. H.C. Wainwright 27th Annual Global Investment... Read More

Eligible patients can receive TTFields therapy through the Spanish National Health System BAAR, Switzerland / Aug 25, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that Spain’s Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma. “Glioblastoma is one of the most... Read More

BAAR, Switzerland / Aug 20, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. This submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitantly with gemcitabine and... Read More

Quarterly net revenues of $159 million, up 6% year-over-year, with 4,331 active patients on therapy as of June 30, 2025 Results from Phase 3 PANOVA-3 clinical trial presented at 2025 ASCO Annual Meeting and ESMO Gastrointestinal Cancers Congress 2025, selected as Best of ASCO 2025 and published in the Journal of Clinical Oncology BAAR, Switzerland / Jul 24, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today reported... Read More

TTFields therapy concomitant with gemcitabine and nab-paclitaxel demonstrated a statistically significant and clinically meaningful benefit across multiple measures of pain and in a post-hoc analysis significantly delayed the need for opioid pain medication for patients with unresectable, locally advanced pancreatic adenocarcinoma A significant delay in deterioration across measures of health status was observed, preserving... Read More

BAAR, Switzerland / Jun 30, 2025 / Business Wire / Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, July 24, to discuss the company’s financial results for the three- and six-month periods that ended June 30, 2025. To access the conference call by phone, use... Read More

TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome... Read More

BAAR, Switzerland / May 27, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. PANOVA-3 Investor Event, May 31, 2025 : Novocure will host investors on Saturday, May 31 at 8:00 p.m. ET / 7:00 p.m. CT in Chicago to review data from the successful Phase 3 PANOVA-3 clinical trial in unresectable, locally advanced pancreatic cancer. Novocure leadership... Read More

Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as late-breaking abstract for presentation at 2025 American Society of Clinical Oncology Annual Meeting CE Mark approval received for Optune Lua for use concurrently with immune checkpoint inhibitor or docetaxel in adult patients with... Read More

BAAR, Switzerland / Apr 23, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will present additional results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for pancreatic cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 in Chicago. The PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with... Read More

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark approval is supported by the Phase 3 LUNAR trial, which demonstrated the first substantial improvement in median overall survival in more than 8 years for this patient population Optune Lua is a wearable medical device that... Read More

BAAR, Switzerland / Apr 01, 2025 / Business Wire / Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, April 24, to discuss the company’s financial results for the three-month quarter that ended March 31, 2025. To access the conference call by phone, use the... Read More

BAAR, Switzerland / Mar 04, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will take part in a fireside chat at 4:20 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the... Read More

Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial rollout underway in the U.S. Phase 3 PANOVA-3 trial met primary endpoint, demonstrating statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic cancer BAAR, Switzerland... Read More

Preliminary full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Novocure to present at the 43 rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 BAAR, Switzerland / Jan 13, 2025 / Business Wire / Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024.... Read More

BAAR, Switzerland / Jan 03, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in the 43 rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Ashley Cordova, Chief Executive Officer, and William Doyle, Executive Chairman, will speak on behalf of the company and address questions at 9:00 a.m. PST. Ms. Cordova and Mr. Doyle will be joined by Christoph... Read More

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the first line with TTFields concomitant with gemcitabine and nab-paclitaxel Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets Full results from the PANOVA-3 trial will be presented at an upcoming... Read More

ROOT, Switzerland / Nov 27, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables, Florida. William Doyle, Executive Chairman, will take part in a fireside chat at 2:10 p.m. ET. Piper Sandler Healthcare Conference on Thursday, December 5, 2024, in New York City.... Read More

ROOT, Switzerland / Nov 21, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas. Novocure will present the results of its work to design arrays that will allow efficient and stable delivery... Read More

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users ROOT, Switzerland / Nov 21, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM). Optune Gio is a wearable,... Read More

ROOT, Switzerland / Oct 30, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that Christoph Brackmann has been appointed as the company’s next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he... Read More

Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua ® for the treatment of metastatic non-small cell lung cancer After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cordova Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025... Read More

The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results of the pivotal Phase 3 LUNAR trial represent the first substantial improvement in median overall survival in more than 8 years for this patient population Optune Lua is a wearable treatment... Read More

ROOT, Switzerland / Oct 01, 2024 / Business Wire / Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company’s financial results for the three-month quarter and first nine months of the year that ended September 30,... Read More

ROOT, Switzerland / Sep 09, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain. The results of the real-world analysis suggest higher TTFields... Read More

After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO ROOT, Switzerland / Sep 03, 2024 / Business Wire / Novocure (NASDAQ: NVCR)... Read More

ROOT, Switzerland / Aug 28, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. William Doyle, Novocure’s Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed... Read More

ROOT, Switzerland / Aug 14, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC) from September 7 – 10, 2024 in San Diego, California. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor... Read More

Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 ROOT, Switzerland / Jul 25, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working... Read More

ROOT, Switzerland / Jul 01, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To... Read More

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with TTFields therapy and supportive care compared to 11.3 months for patients treated with supportive care alone Patients treated with TTFields therapy experienced prolonged quality of life deterioration-free survival and TTFields therapy was well-tolerated Data from the METIS trial to be presented today during the 2024... Read More

Use of proceeds to fund working capital needs stemming from Novocure’s anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure’s convertible notes ROOT, Switzerland / May 02, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed... Read More

Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR PMA application for TTFields in NSCLC Day 100 FDA meeting complete ROOT, Switzerland / May 02, 2024 / Business Wire / Novocure (NASDAQ: NVCR)... Read More

ROOT, Switzerland / Apr 24, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without... Read More

ROOT, Switzerland / Apr 05, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 in San Diego. The presentations, describing preclinical investigations, include new insights on how TTFields therapy can potentially enhance the immune... Read More

ROOT, Switzerland / Apr 01, 2024 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the... Read More

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone Novocure to host investor conference call at 8 a.m. EDT ROOT, Switzerland / Mar 27, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint,... Read More

Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone ROOT, Switzerland / Mar 11, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results... Read More

Full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC accepted for review by U.S. Food and Drug Administration Enrollment completed in phase 3 TRIDENT trial studying the use of TTFields therapy and concomitant radiation for the treatment of newly diagnosed GBM ROOT, Switzerland / Feb 22, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today reported... Read More

ROOT, Switzerland / Jan 18, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of non-small cell lung cancer (NSCLC), following progression on or after platinum-based therapy, has been accepted for filing by the U.S. Food and Drug... Read More

Final data from the TRIDENT trial anticipated in 2026 ROOT, Switzerland / Jan 09, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the global phase 3 TRIDENT clinical trial evaluating the safety and efficacy of initiating Optune Gio ® (formerly known as Optune ® ) concurrent with radiation therapy and temozolomide (TMZ) for the treatment of adult patients with newly... Read More

Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D., Ph.D. appointed as Novocure Chief Medical Officer, effective January 1, 2024 Novocure to present at the 42 nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PST on Wednesday, January 10, 2024 ROOT,... Read More

ROOT, Switzerland / Jan 04, 2024 / Business Wire / Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist and educator. At Novocure, Dr. Leupin will oversee medical... Read More

ROOT, Switzerland / Dec 27, 2023 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in the 42 nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on Wednesday, January 10, 2024. Mr. Doyle and Ashley Cordova, Novocure’s Chief Financial... Read More

Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating expenses of approximately $60 million, including a reduction in headcount of approximately 200 colleagues, 13% of total workforce ROOT, Switzerland / Nov 28, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced a series of... Read More

ROOT, Switzerland / Nov 21, 2023 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in the 35 th Annual Piper Sandler Healthcare Conference on Wednesday, November 29, 2023. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will take part in a fireside chat at 3:30 p.m. EST, as well as one-on-one meetings with investors throughout the... Read More

ROOT, Switzerland / Nov 10, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced that research on Tumor Treating Fields (TTFields) therapy, including new data from the phase 2 2-THE-TOP trial and real-world evidence from patients diagnosed with glioblastoma (GBM) and other central nervous system tumors (CNS), will be presented at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting from Nov. 16 to Nov. 19 in... Read More

Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 ROOT, Switzerland / Oct 26, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor... Read More

Highlights include a new analysis showing that Tumor Treating Fields therapy, when added to standard systemic therapies, did not adversely affect patients’ quality of life in the phase 3 LUNAR clinical trial. ROOT, Switzerland / Oct 15, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced its participation in the European Society for Medical Oncology (ESMO) Congress 2023 from October 20 – 24 in Madrid. Novocure... Read More

ROOT, Switzerland / Oct 12, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of... Read More

ROOT, Switzerland / Oct 02, 2023 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and nine months ended September 30, 2023, at 8 a.m. EDT on Thursday, October 26,... Read More

ROOT, Switzerland / Sep 29, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced its participation in the upcoming American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting from October 1 – 4 in San Diego. Presentations will describe preclinical, clinical and simulation modeling studies on Tumor Treating Fields (TTFields) therapy, including new insights about methods to optimize TTFields intensities... Read More

Presentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancer ROOT, Switzerland / Sep 08, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore. Novocure will take part in... Read More

ROOT, Switzerland / Aug 29, 2023 / Business Wire / Novocure (NASDAQ: NVCR) announced today that data from the randomized phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer (NSCLC) following progression on or after platinum-based therapy have been published in The Lancet Oncology . As... Read More

ROOT, Switzerland / Aug 28, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced that the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of Tumor Treating Fields (TTFields) together with paclitaxel in patients with platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival (OS) at the final analysis. Patients randomized to receive TTFields therapy plus paclitaxel (n=280)... Read More

ROOT, Switzerland / Aug 25, 2023 / Business Wire / Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences. William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in the 2023 Wells Fargo Healthcare Conference on September 7, 2023. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 12:45 p.m. ET,... Read More

Quarterly net revenues of $126 million with 3,571 active patients on therapy as of June 30, 2023 Phase 3 LUNAR trial in non-small cell lung cancer met primary and key secondary survival endpoints, the first of four phase 3 trials to readout by year-end 2024 Interim analysis for fully enrolled phase 3 PANOVA-3 trial in pancreatic cancer concluded with recommendation to proceed to final analysis ROOT, Switzerland / Jul 27,... Read More

Pre-specified interim analysis concluded that the fully enrolled PANOVA-3 clinical trial should proceed to final analysis as planned ROOT, Switzerland / Jul 21, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced the results of a pre-specified interim analysis for the phase 3 PANOVA-3 clinical trial evaluating the safety and efficacy of Tumor Treating Fields (TTFields) therapy together with nab-paclitaxel and... Read More

ROOT, Switzerland / Jul 03, 2023 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three and six months ended June 30, 2023, at 8:00 a.m. EDT on Thursday, July 27, 2023. To... Read More

Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more... Read More

ROOT, Switzerland / Jun 01, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer ® , the ASCO Foundation, to advance cancer research and education. Conquer Cancer is a global community of advocates, patients, doctors, researchers, caregivers, and others dedicated to improving the lives of people affected by cancer. Its mission is to accelerate breakthroughs in... Read More

Data from phase 3 LUNAR clinical trial in non-small cell lung cancer to be presented June 6 th at ASCO Annual Meeting Enrollment of phase 3 METIS clinical trial completed, the fourth phase 3 clinical trial to complete enrollment in last 18 months ROOT, Switzerland / May 04, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2023. Novocure is a global oncology... Read More

ROOT, Switzerland / Apr 26, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6. The LUNAR study is a phase 3, open-label, randomized study evaluating the safety and... Read More

ROOT, Switzerland / Apr 14, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced 27 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida. The research described in the presentations includes real-world evidence supporting the safety and efficacy of TTFields therapy in glioblastoma... Read More

ROOT, Switzerland / Apr 03, 2023 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three months ended March 31, 2023, at 8:00 a.m. ET on Thursday, May 4, 2023. To access the... Read More

ROOT, Switzerland / Mar 29, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors. “We look forward to welcoming Ms. Stafford to our board of directors,” said William Doyle, Novocure’s Executive Chairman. “Her broad expertise in finance in the life sciences sector and experience with a leading funder of innovation across the biopharmaceutical... Read More

ROOT, Switzerland / Mar 16, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced the 5 th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields) as well as to encourage investigators to enter the TTFields research field. The... Read More

ROOT, Switzerland / Mar 01, 2023 / Business Wire / Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering Optune on the List of Reimbursable Products and Services (LPPR) provided for in Article L165-1 of the Social Security Code was published in the... Read More

ROOT, Switzerland / Mar 01, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patients with brain metastases resulting from non-small cell lung cancer (NSCLC). “We are pleased to announce the completion of enrollment in the... Read More

ROOT, Switzerland / Feb 23, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors. “We are honored to welcome Dr. Ocean to our board of directors,” said William Doyle, Novocure’s Executive Chairman. “With her extensive expertise in gastrointestinal oncology and as a practicing clinician, Dr. Ocean will provide important insights and... Read More

ROOT, Switzerland / Feb 15, 2023 / Business Wire / Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of patients with locally advanced pancreatic cancer. “There is a severe unmet need for patients with pancreatic cancer,” said Asaf Danziger,... Read More

Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17. Pritesh Shah, Novocure’s Chief Commercial Officer, will transition into a new executive role as Chief Growth Officer. In this role, Mr. Shah will have worldwide responsibilities for product and portfolio strategy, brand management, establishing a global framework for new launches, market access and market... Read More

Preliminary full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival Novocure announces first patients treated with new arrays Novocure to present at the 41 st Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PST on Tuesday, Jan. 10, 2023... Read More

The LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival The full LUNAR data will be presented at a future medical congress Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in overall survival over standard therapies alone. The... Read More

Novocure (NASDAQ: NVCR) announced today it will participate in the 41 st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at 7:30 a.m. PST on January 10, 2023. Mr. Doyle and Ashley Cordova, Novocure’s Chief Financial Officer, will also participate in one-on-one meetings with investors... Read More